Navigation Links
Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target
Date:1/6/2009

SEATTLE, Jan. 6 /PRNewswire/ -- Omeros Corporation today announced that The Michael J. Fox Foundation has awarded it a $465,000 grant against milestones to support the Company's collaboration with The Parkinson's Institute to evaluate Omeros' recent discovery of a new target for the treatment of Parkinson's disease. Located in regions of the brain responsible for Parkinson's disease, Omeros is the first to link its novel target to the treatment of any movement disorder, including Parkinson's disease and Restless Legs Syndrome. Omeros will continue to retain all of its rights associated with this novel target.

"We are pleased that The Michael J. Fox Foundation is joining our efforts to develop a novel treatment for Parkinson's disease," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "The Foundation is a well-recognized leader in Parkinson's research, and its support will be key to testing the potential of our proprietary approach for treating patients living with the disease."

Under Omeros' collaboration with The Parkinson's Institute, preclinical studies using a widely accepted and highly predictive model for the symptomatic treatment of Parkinson's disease are being conducted on one or more compounds that block Omeros' proprietary target. Omeros' earlier studies conducted at Emory University by Gary W. Miller, Ph.D. in a similar model showed that compounds blocking this novel target were as effective as levodopa, or L-DOPA, at doses 50- to 100-times lower than those of L-DOPA. L-DOPA has been the standard treatment for Parkinson's disease for nearly 40 years but is associated with profound side effects including dyskinesias, hallucinations, sleep disorders and cognitive impairment. Omeros plans to explore the clinical utility of one or more of the compounds currently under evaluation both singly and in conjunction with L-DOPA.

Parkinson's disease, a degenerative disorder of the central nervous system, often impairs motor skills, speech and other functions. It is estimated that approximately 1.5 million people in the U.S. suffer from the disease, and an estimated 60,000 new cases are reported each year.

Restless Legs Syndrome(RLS), also a neurological disorder, is characterized by irritating sensations in the legs and an uncontrollable urge to move them when at rest. If left untreated, it can cause exhaustion and daytime fatigue. RLS is estimated to affect as many as 12 million Americans, but the incidence could be significantly higher due to under- or misdiagnosis.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $130 million in research to date, either directly or through partnerships. For more information, please visit the Foundation's Web site at http://www.michaeljfox.org/.


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
2. Omeros and BlueCrest Announce $20 Million Debt Facility
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros Appoints David A. Mann to its Board of Directors
5. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
6. Probiotic Delivery Technology Awarded Third International Patent
7. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
8. China Medicine Corporation Awarded GSP Certification
9. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
10. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
11. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):